Weight Management

There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.

The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Your daily dose of the clinical news you may have missed.

Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.